Recent Company News

• 02:54 AM ET Dec 03, 2025
  

  StreetAccount Summary - European pre-market trading update

• 02:09 AM ET Dec 03, 2025
  

  Orion receives €180M milestone payment and updates 2025 outlook (€61.30, 0.00)

• 02:44 AM ET Nov 18, 2025
  

  Celltrion receives European Commission approval for Remsima IV liquid formulation (KRW 183800.0000, 0)

• 07:47 PM ET Nov 11, 2025
  

  NICE recommends Orion's Nubeqa with ADT to treat hormone-sensitive metastatic prostate cancer

• 06:50 AM ET Oct 29, 2025
  

  Orion upgraded to buy from accumulate at OP Corporate Bank (pre-European open) (€63.00, +2.00)

• 09:18 AM ET Oct 28, 2025
  

  Transcript Intelligence: Orion Q3 Earnings Themes (€62.60, -5.60)

• 06:04 AM ET Oct 28, 2025
  

  Orion reports Q3 EPS €0.68 vs FactSet €0.69 [7 est, €0.62-0.76]; narrows FY25 outlook (€66.45, -1.75)

• 08:32 AM ET Oct 23, 2025
  

  Orion, Abzena announce exclusive commercial license for Abzena's antibody (€68.05, +0.55)

• 07:11 AM ET Oct 18, 2025
  

  Celcuity presents updated data from Phase 1 trial evaluating gedatolisib in combination with Nubeqa in men with mCRPC ($51.96, 0.00)

• 05:11 AM ET Oct 06, 2025
  

  Celltrion presents positive real-world data on the use of subcutaneous infliximab at MTE Sessions at UEG 2025 (KRW 175400.0000, 0)